Everything below concerns anti-doping analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-24. Numbers and descriptions here follow the published literature rather than marketing material.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
To determine if GSR is present in an area, presumptive tests, such as the modified Griess test and the sodium rhodizonate test, are performed. Any presumptive GSR samples are collected for confirmatory testing using instruments such as Scanning electron microscopy dispersive X-ray spectrometry (SEM-EDX) Flame or Graphite Furnace Atomic Absorption Spectrometry. There are both inorganic and organic components in GSR. Organic GSR (OGSR) consists of organic compounds such as nitroglycerine. Organic compounds can originate from the primer, propellants, lubricants or other additives used by manufacturers. Analysis of OGSR is not done with the same instrumentation as stated above, instead techniques like Gas Chromatography-Mass Spectrometry are used.
In March 2015, Markie Pasternak of Green Bay, Wisconsin, was diagnosed as the youngest person to be living with HSAM. Born in 1994, Pasternak remembers every day of her life since February 2005. She was featured on 60 Minutes Australia in August 2016 with Rebecca Sharrock. In January 2016, painter and polymath Nima Veiseh was featured by the BBC for his use of hyperthymesia to create paintings that were said to only be producible with vast memories of art pieces, although a paper published in the journal Memory in 2022 claimed that having hyperthymesia does not increase one's creative thinking. Veiseh claimed to remember almost every day of his life since he was 15 years old, and that his ability to synthesise time and an "encyclopedic knowledge of the history of art" enabled him to create wholly unique visions on canvas. In March 2016 NPR examined further Veiseh's exploration of time and the human experience through art. In 2017, Australian Rebecca Sharrock of Brisbane became known as a person who claims to recall even circumstantial details of every day of her life from her 12th day of life onward. Discussing her hyperthymesia with BBC World Service, Sharrock revealed she was supporting two research projects – one with the University of Queensland and another with the University of California – to understand how a greater knowledge of hyperthymesia can support Alzheimer's disease research, particularly in repairing the degeneration of the hippocampus.
1993/1250) Aviation Security (Jersey) Order 1993 (S.I. 1993/1251) Financial Provisions (Northern Ireland) Order 1993 (S.I. 1993/1252) Serbia and Montenegro (United Nations Sanctions) (Channel Islands) Order 1993 (S.I. 1993/1253) Serbia and Montenegro (United Nations Sanctions) (Isle of Man) Order 1993 (S.I. 1993/1254) Maximum Number of Judges (No. 2) Order 1993 (S.I. 1993/1255) Arbitration (Foreign Awards) Order 1993 (S.I. 1993/1256) Designs (Convention Countries) Order 1993 (S.I. 1993/1257) Patents and Marks (Convention and Relevant Countries) Order 1993 S.I. 1993/1258) Hackney and Tower Hamlets (London Borough Boundaries) Order 1993 (S.I. 1993/1260) Bromley and Lewisham (London Borough Boundaries) Order 1993 (S.I. 1993/1261) Kensington and Chelsea and Westminster (London Borough Boundaries) Order 1993 (S.I. 1993/1262) Food Premises (Registration) (Welsh Form of Application) Regulations 1993 (S.I. 1993/1270) Greenwich and Lewisham (London Borough Boundaries) Order 1993 (S.I. 1993/1276) Ealing, Hillingdon and Hounslow (London Borough Boundaries) Order 1993 (S.I. 1993/1277) Treatment of Spruce Bark Order 1993 (S.I. 1993/1282) Plant Health (Forestry) (Great Britain) Order 1993 (S.I. 1993/1283) Prohibition of the Keeping or the Release of Live Fish (Pikeperch) (Scotland) Order 1993 (S.I. 1993/1288) A27 Trunk Road (Patching Junction Improvement) Order 1993 (S.I. 1993/1293) A27 Trunk Road (Patching Junction Improvement Slip Roads) Order 1993 (S.I. 1993/1294) A27 Trunk Road (Patching Junction Improvement) (Detrunking) Order 1993 (S.I. 1993/1295)
=== Works cited === This article incorporates text from a publication now in the public domain: Chisholm, Hugh, ed. (1911). "Alum". Encyclopædia Britannica. Vol. 1 (11th ed.). Cambridge University Press. pp. 766–767.
==== Distribution ==== Mescaline is distributed to the liver, spleen, and kidneys at many times higher levels than blood or brain based on animal studies. It is said that a great proportion of mescaline is combined with hepatic proteins, which is said to delay its onset and elimination half-life. The exact portion bound to plasma proteins seems to be unknown, but appears to be minimal. Mescaline appears to have relatively poor blood–brain barrier permeability due to its low lipophilicity. However, it is still able to cross into the central nervous system and produce psychoactive effects at sufficiently high doses. The poor central permeability of mescaline appears to be responsible for its delayed onset of effects and is also thought to contribute to its low potency.
Sources: en.wikipedia.org
=== α/β === α/β proteins are a class of structural domains in which the secondary structure is composed of alternating α-helices and β-strands along the backbone. The β-strands are therefore mostly parallel. Common examples include the flavodoxin fold, the TIM barrel and leucine-rich-repeat (LRR) proteins such as ribonuclease inhibitor.
=== Tolerance and dependence === As with other opioid medications, tolerance and dependence usually develop with repeated doses. There is some clinical evidence that tolerance to analgesia is less with methadone compared to other opioids; this may be due to its activity at the NMDA receptor. Tolerance to the different physiological effects of methadone varies; tolerance to analgesic properties may or may not develop quickly, but tolerance to euphoria usually develops rapidly, whereas tolerance to constipation, sedation, and respiratory depression develops slowly (if ever).
4-Allyl-6-oxa-noribogainalog is a κ-opioid receptor (KOR) agonist of the oxa-ibogalog family related to oxa-noribogaine. It is a highly potent full agonist of the KOR, with an EC50Tooltip half-maximal effective concentration of 1 nM and an EmaxTooltip maximal efficacy of 103% in a G protein BRET assay. This is dramatically more potent than oxa-noribogaine or noribogaine at the KOR in the same assay per another study by the same group (EC50 (Emax) = 43 nM (82%) and 6,100 nM (52%), respectively). The drug shows considerable selectivity for activation of the KOR over activation of the μ- and δ-opioid receptors. 4-Allyl-6-oxa-noribogainalog was the most potent KOR agonist in a series of oxa-ibogalog compounds. It was patented by Dalibor Sames and colleagues in 2025, with Sames being a co-founder of Gilgamesh Pharmaceuticals.
=== Signs === The silhouette sign is especially helpful in localizing lung lesions. (e.g., loss of right heart border in right middle lobe pneumonia), The air bronchogram sign, where branching radiolucent columns of air corresponding to bronchi is seen, usually indicates air-space (alveolar) disease, as from blood, pus, mucus, cells, protein surrounding the air bronchograms. This is seen in Respiratory distress syndrome
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.